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Chromodomain	helicase/ATPase	DNA	binding	protein	1–like	gene	(CHD1L)	is	a	recently	identified	oncogene	
localized	at	1q21,	a	frequently	amplified	region	in	hepatocellular	carcinoma	(HCC).	To	explore	its	oncogenic	
mechanisms,	we	set	out	to	identify	CHD1L-regulated	genes	using	a	chromatin	immunoprecipitation–based	
(ChIP-based)	cloning	strategy	in	a	human	HCC	cell	line.	We	then	further	characterized	1	identified	gene,	
ARHGEF9,	which	encodes	a	specific	guanine	nucleotide	exchange	factor	(GEF)	for	the	Rho	small	GTPase	
Cdc42.	Overexpression	of	ARHGEF9	was	detected	in	approximately	half	the	human	HCC	samples	analyzed	
and	positively	correlated	with	CHD1L	overexpression.	In	vitro	and	in	vivo	functional	studies	in	mice	showed	
that	CHD1L	contributed	to	tumor	cell	migration,	invasion,	and	metastasis	by	increasing	cell	motility	and	
inducing	filopodia	formation	and	epithelial-mesenchymal	transition	(EMT)	via	ARHGEF9-mediated	Cdc42	
activation.	Silencing	ARHGEF9	expression	by	RNAi	effectively	abolished	the	invasive	and	metastatic	abilities	
of	CHD1L	in	mice.	Furthermore,	investigation	of	clinical	HCC	specimens	showed	that	CHD1L	and	ARHGEF9	
were	markedly	overexpressed	in	metastatic	HCC	tissue	compared	with	healthy	tissue.	Increased	expression	
of	CHD1L	was	often	observed	at	the	invasive	front	of	HCC	tumors	and	correlated	with	venous	infiltration,	
microsatellite	tumor	nodule	formation,	and	poor	disease-free	survival.	These	findings	suggest	that	CHD1L-
ARHGEF9-Cdc42-EMT	might	be	a	novel	pathway	involved	in	HCC	progression	and	metastasis.
Introduction
Hepatocellular carcinoma (HCC) is ranked as the fifth most fre-
quent cancer in the world and affects 1 million people annually 
(1). The prognosis of HCC is very poor, and the 5-year survival rate 
worldwide is less than 5%, mainly because of a high potential for 
vascular invasion, metastasis, and recurrence even after surgical 
resection (2). Like other cancers, HCC metastasis is a multistep 
process that includes tumor cells’ invasion of tumor cells into the 
surrounding tissues, entry of tumor cells into the systemic circula-
tion (intravasation), their survival in circulation, extravasation of 
the cells to distant organs, and finally the formation of second-
ary tumors (3). Genetically, the loss of alleles on 16q and 8p has 
been associated with HCC metastasis (4, 5). Recently, several genes 
associated with HCC metastasis have been identified, including 
cortactin (6), CLU (7), HTPAP (8), Twist (9), and Pyk2 (10).
Amplification of 1q21 is one of the most frequent genetic 
alterations in HCC (11–13) and has been associated with HCC 
metastasis (14). Recently, 1 candidate oncogene, chromodomain 
helicase/ATPase DNA binding protein 1–like gene (CHD1L; also 
known as ALC1), has been isolated from the 1q21 amplicon (15). 
Our previous studies have demonstrated that CHD1L is frequently 
amplified and overexpressed in HCCs and plays an important role 
in the development of HCC (15, 16). CHD1L belongs to SNF2-
like subfamily of the sucrose nonfermenting 2 (Snf2) family. Each 
SNF2-like protein contains a domain (approximately 400 amino 
acids) with highly conserved helicase motifs (17). Most SNF2-like 
proteins participate in various nuclear activities, including tran-
scriptional activation or repression, DNA repair, and recombina-
tion (18, 19). These findings prompted us to investigate whether 
CHD1L protein functions as a transcriptional regulator and to 
identify genes potentially regulated by CHD1L.
To identify genes potentially regulated by CHD1L, CHD1L 
DNA-binding sequences were isolated using a chromatin 
immunoprecipitation–based (ChIP-based) cloning strategy (20). 
Using this strategy, 35 CHD1L-binding loci were isolated, and 
genes near these loci were identified by BLAST searches. Of the 
CHD1L-regulated genes, ARHGEF9 was particularly interest-
ing, as it is able to activate the Rho small GTPase Cdc42. One 
of the important molecular mechanisms in cancer metastasis 
is the activation of the Rho family of small GTPases, which in 
turn leads to the rearrangement of the actin cytoskeleton and 
modulates cadherin-dependent cell-cell contacts (21–23). In 
the present study, overexpression of ARHGEF9 was observed in 
51.4% of primary HCC cases and was positively correlated with 
CHD1L expression, which suggests that expression of ARHGEF9 
is regulated by CHD1L. Furthermore, as detected by functional 
studies, upregulation of ARHGEF9 by CHD1L increased the 
Cdc42-GTP level in HCC cells, induced HCC invasion and 
metastasis through the relocalization of actin to filopodia-like 
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structures, and promoted the epithelial-mesenchymal transition 
(EMT). The clinical significance of CHD1L overexpression was 
also addressed in this study.
Results
Identification of CHD1L target genes. Like other SNF2-like family 
members, CHD1L may also be able to regulate gene expression at 
the transcriptional level. To identify genes potentially regulated by 
CHD1L, CHD1L target genes were isolated using a modified ChIP-
based cloning strategy (Figure 1A). Briefly, the CHD1L gene was 
cloned into expressing vector tagged with GFP and stably trans-
fected into the HCC cell line QGY-7703, in which endogenous 
expression of CHD1L is extremely low (15, 16). We selected 2 GFP/
CHD1L transfectants (GFP/CHD1L-7703-C3 and -C6) with high 
expression of the GFP/CHD1L fusion protein and 2 GFP empty 
vector transfectants (GFP-7703-C3 and -C4) for further study 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI40665DS1). Using the strategy 
outlined in Figure 1A, 35 clones were isolated and sequenced. 
To exclude the contamination of GFP-bound DNA fragments, 
a parallel experiment was performed using GFP transfectants 
(GFP-7703-C3 and -C4), from which no clones were obtained.
A BLAST search was used to identify genes near the potential 
CHD1L-binding sites. Among the 35 CHD1L-binding loci, 25 
of 35 (71.4%) CHD1L binding sites were mapped less than 70 kb 
away from known genes; we classified these as 5′ (9 loci), introns 
(12 loci), or 3′ (4 loci; Figure 1B and Supplemental Table 1). All 
35 DNA sequences (mean length, 325 bp) were analyzed by Mat-
Inspector software (Genomatrix) to search for potential CHD1L-
binding motifs (24). An 11-bp SWI/SNF-related DNA-binding 
motif was detected in 17 of 35 (48.6%) CHD1L-binding sequences 
(Supplemental Table 2). The motif contained a hexameric core 
sequence of C/A-C-A/T-T-T-T (Figure 1C) and was similar to a 
known SWI/SNF-related, matrix-associated, actin-dependent 
regulator of chromatin, subfamily a, member 3 (SMARCA3; also 
named SNF2-like 3) motif (25). To confirm the CHD1L-binding 
sites, we used PCR to detect 10 CHD1L-binding sites with the 
CHD1L-binding motif in the ChIP-isolated CHD1L-bound DNA 
fragments using 2 different GFP antibodies, FL and B-2. As expect-
ed, the amplified DNA fragments were detected in ChIP-isolated 
DNA, but not in controls (Figure 1D). These data indicate that 
CHD1L may transcriptionally regulate target genes by binding to 
a specific DNA-binding motif.
CHD1L upregulates ARHGEF9 expression. The CHD1L-regulated 
gene ARHGEF9 was further characterized because of its ability to 
activate the Rho small GTPase Cdc42, which may play a key role 
in tumor metastasis. To confirm that CHD1L protein binds to 
ARHGEF9, EMSA was performed using an oligonucleotide probe 
from the ARHGEF9 locus (CHD1L_57; Supplemental Figure 
1B). CHD1L specifically bound to the digoxigenin-labeled (DIG-
labeled) probe (Figure 2A). To determine whether the expression 
of ARHGEF9 was modulated in a CHD1L-dependent manner, 
the CHD1L gene was transiently transfected into the HCC cell 
line QGY-7703 and into immortalized liver cell line LO-2, and the 
effect of ectopic expression of CHD1L on ARHGEF9 expression 
was tested by quantitative real-time PCR (qPCR). As shown in Fig-
ure 2B, ARHGEF9 expression was upregulated by CHD1L. Fur-
thermore, decreased expression of ARHGEF9 was detected when 
CHD1L expression was silenced in the HCC cell line PLC8024 by 
RNAi with an siRNA against CHD1L (siCHD1L), but not with an 
siRNA against GAPDH (siGAPDH; Figure 2C).
CHD1L activates Cdc42 through ARHGEF9 upregulation. As ARHGEF9 
is a guanine nucleotide exchange factor (GEF) specific for Cdc42 
(26), we investigated whether CHD1L could activate Cdc42 
through the upregulation of ARHGEF9 in HCC cells. For this 
purpose, CHD1L was stably transfected into QGY-7703 and LO-2 
cells (referred to herein as CHD1L-7703 and CHD1L-LO2, respec-
tively), and empty vector was used as a control (referred to as 
Vec-7703 and Vec-LO2). Ectopic expression of CHD1L 
upregulated ARHGEF9 expression, which subsequently activated 
Figure 1
Identification of CHD1L target genes and the putative CHD1L-binding motif. (A) Genome-wide mapping of CHD1L target genes using a modified 
ChIP-based cloning approach. Cultured cells were treated with formaldehyde to crosslink protein-DNA complexes. A specific antibody was used 
to capture CHD1L-bound DNA sequences by immunoprecipitation. The precipitated DNA fragments were ligated to an adaptor, cloned into the 
pGEM-T vector, and analyzed by sequencing. (B) Distribution of CHD1L-binding loci, indicated by triangles. (C) Top-scoring motif identified in an 
unbiased analysis of CHD1L target genes using MatInspector software. The height of each letter is proportional to its frequency. (D) Confirmation 
of 10 randomly selected CHD1L target genes by ChIP-PCR using anti-GFP antibodies FL and B-2 or pooled IgG from mouse and rabbit (negative 
control) in GFP/CHD1L-7703-C3 cells. Input represents amplification of a 1:50 dilution of total input chromatin.
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Cdc42 (Figure 2D). As shown in Figure 2E, increased Cdc42-GTP, 
the active form of Cdc42, was detected in both CHD1L-7703 and 
CHD1L-LO2 cells compared with Vec-7703 and Vec-LO2 cells. 
These results suggested that CHD1L could active Cdc42 by the 
upregulation of ARHGEF9.
CHD1L induces filopodia formation and EMT. We next investigated 
whether CHD1L overexpression affects the actin cytoskeleton in 
HCC cell lines, because Cdc42 can promote actin filament assem-
bly and filopodia formation (27). First, we found that the cell mor-
phology of CHD1L-LO2 and CHD1L-7703 cells changed from an 
epithelial-like to a fibroblastic-like morphology (Figure 3A), which 
suggests that these cells underwent a rearrangement of the cyto-
skeleton. F-actin staining showed that filopodia formation dra-
matically increased in CHD1L-7703 cells, suggestive of substantial 
relocalization of actin to filopodia in these cells (Figure 3B).
Since rearrangement of the actin cytoskeleton is often regarded as 
a signature of the EMT, the effect of CHD1L on the EMT was inves-
tigated. The expression of 3 tested epithelial markers (E-cadherin, 
α-catenin, and β-catenin) decreased, while the expression of 4 
tested mesenchymal markers (N-cadherin, vimentin, fibronectin, 
and α-SMA) increased, in CHD1L-expressing cells compared with 
empty vector–transfected cells (Figure 3C). Because the downregu-
lation of E-cadherin has been closely associated with EMT, and 
loss of E-cadherin leads to the accumulation of β-catenin in the 
cytoplasm and/or nucleus (28), double immunofluorescence (IF) 
staining of E-cadherin and β-catenin was performed in Vec-7703 
and CHD1L-7703 cells to further investigate the effect of CHD1L 
on the E-cadherin/β-catenin complex. Membranous expression 
of both E-cadherin and β-catenin decreased in CHD1L-7703 cells 
compared with Vec-7703 cells; however, no obvious accumulation 
of β-catenin in the nucleus was observed (Figure 3D). IF staining 
also confirmed increased expression of the mesenchymal mark-
ers fibronectin and vimentin in CHD1L-7703 cells compared with 
Vec-7703 cells (Figure 3E). All these results demonstrated that 
CHD1L-7703 cells underwent EMT.
CHD1L increases cell motility and invasion. The EMT promotes 
tumor progression by increasing the invasiveness and migra-
tory capacity of the tumor cell. To test whether CHD1L-7703 
and CHD1L-LO2 cells acquired greater migratory and invasive 
capabilities, an in vitro scratch wound healing assay and a Matri-
gel invasion assay were performed. The wound healing assay 
demonstrated that the ectopic expression of CHD1L increased 
cell motility in both CHD1L-7703 and CHD1L-LO2 cells com-
pared with Vec-7703 and Vec-LO2 cells (Figure 3F). Similarly, 
the Matrigel invasion assay showed that the invasiveness of the 
CHD1L-expressing cells was significantly higher than empty 
vector–transfected cells (P < 0.001, independent Student’s t test; 
Supplemental Figure 2 and Figure 3G).
ARHGEF9 is responsible for CHD1L-induced Cdc42 activation. 
To investigate whether activation of Cdc42 by ARHGEF9 is 
responsible for CHD1L-induced filopodia formation, EMT, and 
tumor invasion, RNAi was used to silence ARHGEF9 expression. 
CHD1L-7703 cells were treated with siRNAs against ARHGEF9 
(siARHGEF9-1 or siARHGEF9-2) or siGAPDH as a negative con-
trol. After siRNA treatment, the expression of ARHGEF9 was 
dramatically decreased (Supplemental Figure 3A), which resulted 
Figure 2
ARHGEF9 is a validated target gene of CHD1L and induces Cdc42 activation. (A) EMSA was used to detect the interaction between CHD1L and 
ARHGEF9 double-stranded DNA probes. Lane 1, without NE; lane 2, with NE from GFP-7703-C4 cells and DIG-labeled probe; lane 3, with NE 
from GFP/CHD1L-7703-C3 cells and labeled probe; lane 4, same as lane 3 plus a 50-fold molar excess of unlabeled probe; lane 5, same as lane 
3 plus excess unlabeled nonspecific probe. (B) ARHGEF9 expression was modulated by CHD1L. After transient transfection, relative expres-
sion of CHD1L and ARHGEF9 was detected in Vec-7703, CHD1L-7703, Vec-LO2, and CHD1L-LO2 cells by qPCR. 18S rRNA was used as an 
internal control. (C) Silencing CHD1L expression downregulated ARHGEF9 expression. PLC8024 cells were treated with siCHD1L or siGAPDH 
as a negative control. The fold changes in CHD1L, ARHGEF9, and GAPDH expression in siCHD1L- or siGAPDH-treated PLC8024 cells were 
detected by qPCR. (D) Compared with empty vector transfectants, ARHGEF9 expression was upregulated in QGY-7703 and LO-2 cells stably 
expressing CHD1L, as detected by RT-PCR. 18S rRNA was used an endogenous control. (E) Expression of CHD1L, Cdc42-GTP, and total 
Cdc42, detected by Western blot. Cdc42-GTP increased in CHD1L-7703 and CHD1L-LO2 cells. β-Actin was used as a loading control.
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in the reduced expression of Cdc42-GTP (Figure 4A). CHD1L-
induced EMT was also blocked by ARHGEF9 siRNA treatment, 
as evidenced by the increased E-cadherin and decreased vimentin 
expression as well as by the decreased CHD1L-mediated filopodia 
formation (Figure 4, A and B). More importantly, CHD1L-7703 
cells lost their invasive ability after the ARHGEF9 siRNA treat-
ment. Matrigel invasion assay showed that cell invasion signifi-
cantly decreased in siARHGEF9-1– and siARHGEF9-2–treated 
compared with siGAPDH-treated or untreated CHD1L-7703 cells 
(P < 0.001, independent Student’s t test; Figure 4C and Supple-
Figure 3
CHD1L induces filopodia formation, EMT, and cell migration and invasion. (A) Representative images of cell morphology in Vec-LO2, CHD1L-
LO2, Vec-7703, and CHD1L-7703 cells. (B) Redistribution of actin filaments to filopodia-like structures in CHD1L-7703 cells (arrows). The cells 
were stained for F-actin and counterstained with DAPI to visualize the nuclei. (C) Expression of epithelial markers (E-cadherin, α-catenin, and 
β-catenin) and mesenchymal markers (fibronectin, N-cadherin, vimentin, and α-SMA), compared between Vec-7703 and CHD1L-7703 cells by 
Western blot. (D) Double IF staining of E-cadherin and β-catenin was performed in Vec-7703 and CHD1L-7703 cells. Arrows denote the regions 
shown at higher magnification in the insets. (E) Fibronectin and vimentin in Vec-7703 and CHD1L-7703 cells were compared by IF staining; 
nuclei were counterstained with DAPI. (F) Cell migration rates of Vec-7703, CHD1L-7703, Vec-LO2, and CHD1L-LO2 cells were compared via 
wound healing assays. Microscopic observation was recorded at 0, 24, and 36 hours after scratching the surface of a confluent layer of cells. 
(G) Invasion rates of Vec-7703, CHD1L-7703, Vec-LO2, and CHD1L-LO2 cells. Number of cells that invaded through the Matrigel was counted 
in 10 fields under the ×20 objective lens. Original magnification, ×200 (A); ×400 (B, D, and E); ×1,000 (D, insets); ×100 (F).
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mental Figure 3B). All these data suggest that CHD1L-induced 
filopodia formation, EMT, and tumor invasion are associated 
with ARHGEF9-induced activation of Cdc42 in HCC cells.
CHD1L promotes tumor metastasis in SCID mice. To investigate 
the in vivo effects of CHD1L overexpression on metastasis, an 
experimental metastasis assay was used to compare the meta-
static nodules formed in the lungs and livers of SCID mice after 
inoculation with CHD1L-expressing or empty vector–transfect-
ed cells. At 8 weeks after injection, the mice were euthanized, and 
the lungs and livers were harvested. The number of metastatic 
nodules on the surface of the liver was significantly higher in 
mice injected with CHD1L-7703 cells than in mice injected with 
Vec-7703 cells (56 ± 17 versus 6.7 ± 5.6; P < 0.001, independent 
Student’s t test; Figure 5A). Similarly, the number of metastatic 
nodules on the surface of the lungs was significantly higher in 
mice injected with CHD1L-7703 cells than in mice injected with 
Vec-7703 cells (17.8 ± 7.7 versus 3.5 ± 4.4; P < 0.05, independent 
Student’s t test; Figure 5B). Histological studies confirmed that 
the lesions were caused by extravasation and subsequent tumor 
growth of CHD1L-transfected HCC cells into the lungs and liv-
ers (Figure 5, C and D).
CHD1L promotes invasion and metastasis via EMT. To further 
elucidate the invasive function of CHD1L in vivo, we examined 
whether HCC cell lines with a high expression of CHD1L under-
go EMT during tumor progression. For this purpose, Vec-7703 
and CHD1L-7703 cells, or Vec-LO2 and CHD1L-LO2 cells, were 
subcutaneously injected into the dorsal flanks of nude mice 
(n = 5 per group). Consistent with our previous study (15), tumor 
formation was observed in 4 of 5 and 1 of 5 CHD1L-7703– and 
Vec-7703–injected nude mice, respectively, and in 5 of 5 and 1 of 
5 CHD1L-LO2– and Vec-LO2–injected nude mice, respectively 
(Figure 6A and Supplemental Table 3). A clear boundary between 
the tumor and its adjacent nontumor tissue was often observed 
in Vec-7703– or Vec-LO2–generated tumors; however, irregular 
Figure 4
ARHGEF9 is responsible for CHD1L-induced Cdc42 activation, filopodia formation, EMT, and tumor cell migration and invasion. (A) After silencing 
ARHGEF9 expression in CHD1L-7703 cells after treatment with siARHGEF9-1 or siARHGEF9-2, expression of Cdc42-GTP and vimentin decreased, 
whereas expression of E-cadherin and β-catenin increased, relative to untreated or siGAPDH-treated cells. β-actin was used as a loading control. 
(B) Staining for F-actin demonstrated that filopodia formation in siARHGEF9-treated cells dramatically decreased compared with siGAPDH- 
treated cells. IF staining showed increased expression of E-cadherin (green) and decreased expression of vimentin (green) in CHD1L-7703 
cells treated with siARHGEF9-1 or siARHGEF9-2 compared with untreated or siGAPDH-treated cells. Original magnification, ×400. (C) Invasive 
ability was inhibited in CHDL1-7703 cells treated with siARHGEF9-1 and siARHGEF9-2, detected by Matrigel invasion assays. Number of cells 
that invaded through the Matrigel was counted in 10 fields under the ×20 objective lens. **P < 0.001, independent Student’s t test.
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tumor invasion was frequently observed in tumors induced by 
CHD1L-7703 or CHD1L-LO2 cells (Figure 6B, top). Furthermore, 
tumor microsatellite formations were observed near tumors in 2 
of 4 and 3 of 5 CHD1L-7703– and CHD1L-LO2–derived tumors, 
respectively (Figure 6C, top). Immunohistochemical staining 
(IHC) with an anti-CHD1L antibody confirmed the expression 
of CHD1L in CHD1L-LO2– and CHD1L-7703–generated tumors 
(Figure 6, B and C, bottom).
To determine whether the EMT plays a role in tumor metastasis 
induced by CHD1L transfectants in the nude mouse, IHC with 
antibodies against E-cadherin and vimentin was performed on 
serial sections of each tumor. Decreased expression of E-cadherin 
and increased expression of vimentin was observed in tumors 
induced by CHD1L-LO2 or CHD1L-7703 cells compared with 
tumors induced by Vec-LO2 or Vec-7703 cells (Figure 6D). This 
suggests that the EMT promoted by CHD1L may play a key role in 
HCC invasion and metastasis.
CHD1L depletion reverses the invasive process of HCC cells and tumorigen-
esis in nude mice. We then examined whether CHD1L is required for 
the invasive and tumorigenic phenotypes of HCC cells by express-
ing shRNA to knock down CHD1L expression. We stably expressed 
shRNA from 2 different CHD1L sequences (shRNA1 and shRNA2) 
in the HCC cell line PLC8024 (referred to herein as shCHD1L-1– 
8024 and shCHD1L-2–8024 cells). Compared with PLC8024 
cells expressing a control shRNA whose sequence did not match 
any known human gene (Con-8024 cells), expression of CHD1L 
dramatically decreased in shCHD1L-1–8024 and shCHD1L-2– 
8024 cells, as detected by qPCR and Western blot analysis (Figure 7, 
Figure 5
CHD1L promotes tumor metastasis in vivo. (A and B) Metastatic nodules (arrows) on the surface of the liver (A) and lung (B). Below, the number of 
nodules were quantified on livers and lungs of SCID mice (n = 6 per group) 8 weeks after tail vein injection of Vec-7703 (red bars) and CHD1L-7703 
(blue bars) cells. Values for individual mice are shown above the bars; values by group are also denoted. (C and D) H&E staining and IHC 
staining with an anti-CHD1L antibody were performed on serial sections of metastatic tumors (M) and normal (N) liver (C) and lung (D). Original 
magnification, ×200 (top and middle rows); ×400 (bottom row).
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A and C). Moreover, CHD1L knockdown in shCHD1L-1–8024 and 
shCHD1L-2–8024 cells decreased the expression of ARHGEF9 and 
Cdc42-GTP, which in turn led to decreased formation of filopodia, 
upregulation of E-cadherin, and downregulation of vimentin, final-
ly reducing the cells’ invasive ability (Figure 7, A–E). We next sub-
cutaneously injected pooled shCHD1L-1–8024 and shCHD1L-2– 
8024 (referred to as shCHD1L-8024) and Con-8024 cells into nude 
mice. In contrast to Con-8024 cells (all 6 of which formed large 
tumors within 6 weeks), the mice injected with shCHD1L-8024 
cells displayed either no tumor (4 of 6) or greatly reduced tumor 
growth (2 of 6; Figure 7F). The mean volume of tumors induced by 
Con-8024 cells was 6.5-fold larger than that induced by shCHD1L-
8024 cells (P < 0.05, paired Student’s t test; Figure 7G). Increased 
expression of E-cadherin at cell borders and decreased expression 
of vimentin was observed in tumors induced by shCHD1L-8024 
cells compared with those induced by Con-8024 cells (Figure 7H). 
Figure 6
CHD1L promotes tumor invasion and metastasis in nude mice through the EMT. (A) Representative images of the tumors (arrows) formed 
in nude mice induced by vector-transfected cells (left dorsal flank) and CHD1L-expressing cells (right dorsal flank). Red outlines denote the 
tumor mass (A, right). (B) Tumors induced by vector-transfected cells had a clear boundary between the tumor and adjacent nontumor tissue, 
as detected by H&E staining. However, tumors induced by CHD1L-expressing cells displayed irregular invasive fronts. CHD1L expression was 
examined by IHC with an anti-CHD1L antibody in CHD1L-7703– or CHD1L-LO2–derived tumors and their control counterparts. Higher-magnifi-
cation views are shown in the insets. (C) Representative microsatellite tumor formation was observed in the tumors induced by CHD1L-LO2 cells. 
Arrows denote the regions shown at higher magnification in the insets. (D) IHC staining for E-cadherin and vimentin on serial sections of tumors 
induced by Vec-7703, CHD1L-7702, Vec-LO2, and CHD1L-LO2 cells. Original magnification, ×100 (B and C); ×400 (B and C, insets, and D).
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Figure 7
Silencing CHD1L expression inhibits its invasive and tumorigenic ability. (A) Compared with Con-8024 cells, CHD1L and ARHGEF9 expression 
decreased in shCHD1L-1–8024 and shCHD1L-2–8024 cells, as detected by qPCR. (B) Expression of Cdc42-GTP and total Cdc42 was detected 
by Western blot analysis. β-Actin was used as a loading control. (C) Expression of CHD1L, E-cadherin, β-catenin, N-cadherin, and vimentin 
was compared among 3 cell lines by Western blotting and quantified by densitometry (normalized to β-actin). (D) Representative images show-
ing decreased formation of filopodia (arrows), increased expression of E-cadherin, and decreased expression of vimentin in shCHD1L-1–8024 
and shCHD1L-2–8024 cells compared with Con-8024 cells. Nuclei were counterstained with DAPI. (E) Number of cells that invaded through 
the Matrigel was counted in 10 fields under the ×20 objective lens. (F) Reduced tumor volume or absent tumor formation was observed in mice 
injected with shCHD1L-8024 cells. (G) The mean volume of tumors induced by Con-8024 cells was significantly larger than that induced by 
shCHD1L-8024 cells on the sixth week after injection (n = 6). (H) IHC staining for E-cadherin and vimentin on serial sections of tumors induced 
by Con-8024 and shCHD1L-8024. Original magnification, ×400 (D and H).
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All these data indicated that knockdown of CHD1L expression 
may abolish its invasive and tumorigenic abilities through the 
ARHGEF9-Cdc42-EMT pathway.
CHD1L upregulates ARHGEF9 expression in clinical HCC specimens. 
To further investigate whether the CHD1L-ARHGEF9 path-
way is involved in HCC progression, the relationship of CHD1L 
overexpression with ARHGEF9 expression was tested by qPCR 
in 35 pairs of HCC cases. Compared with the paired nontumor 
tissues, overexpression (defined as greater than a 2-fold increase) 
of CHD1L and ARHGEF9 was detected in 20 of 35 (57.1%) and 
18 of 35 (51.4%) HCCs, respectively. The average fold change of 
CHD1L expression in tumor tissues was significantly higher than 
that in paired nontumor tissues (3.85 versus 1.23; P < 0.001, paired 
Student’s t test; Figure 8A). Similarly, the average fold change of 
ARHGEF9 expression in tumor tissues was significantly high-
er than that in their paired nontumor tissues (2.02 versus 0.91; 
P < 0.05, paired Student’s t test; Figure 8A). Furthermore, an asso-
ciation study showed that ARHGEF9 expression positively corre-
lated with CHD1L expression in these 35 pairs of HCC specimens 
(r = 0.722; P < 0.001, Pearson χ2 test; Figure 8B).
The CHD1L-ARHGEF9-Cdc42 pathway promotes EMT in HCC. To fur-
ther confirm the effect of the CHD1L-ARHGEF9-Cdc42 pathway 
on HCC progression, the correlation among CHD1L, ARHGEF9, 
and Cdc42 was investigated in primary HCC specimens. Only 16 of 
35 of HCCs used in the above experiment were included, selected 
because they had both RNA and protein samples available. To con-
firm the association between CHD1L amplification and CHD1L 
overexpression, FISH was used to detect DNA copy number of 
CHD1L in 9 HCC cases using a BAC probe containing CHD1L 
gene and chromosome 1 centromere probe as control. The results 
showed that gain of CHD1L copy number was detected in 5 of 9 
HCC cases (HCC1–HCC5), perfectly consistent with the CHD1L 
overexpression in HCC1–HCC5 detected by Western blot analy-
sis (Figure 8D). Consistent with the correlation study described 
above, the expression of ARHGEF9 detected by RT-PCR also cor-
related closely with CHD1L expression (Figure 8E).
Next, we investigated the association among CHD1L-induced 
ARHGEF9 upregulation, Cdc42 activation, and the EMT pheno-
type in HCC cases. As shown in Figure 8F, increased expression of 
Cdc42-GTP, accompanied by decreased expression of E-cadherin 
Figure 8
CHD1L overexpression correlates with ARHGEF9-meidated Cdc42 activation and EMT in human HCC. (A) Relative expression level of CHD1L 
and ARHGEF9 in 35 paired HCC and nontumor tissues, detected by qPCR. *P < 0.05, **P < 0.001, paired Student’s t test. The boxes represent 
the lower and upper fold change; lines within boxes and whiskers denote mean and SD, respectively. (B) Correlation between CHD1L and ARH-
GEF9 expression in 35 paired HCCs and matched nontumor tissues, with linear regression lines and Pearson correlation significance (P < 0.001, 
Pearson χ2 test). (C) Representative examples (cases HCC1, HCC2, and HCC4; see D) of CHD1L amplification in HCC specimens detected by 
FISH. Green signals represent BAC probe containing CHD1L gene; red signals represent centromere of chromosome 1. Original magnification, 
×1,000. (D) Western blot analysis of CHD1L in 9 representative primary HCC tissues (T) and their paired nontumor (N) tissues. GAPDH was 
used as a loading control. (E) mRNA expression of ARHGEF9 detected by RT-PCR. (F) Western blot analysis was used to determine expression 
levels of total Cdc42, Cdc42-GTP, vimentin, and E-cadherin in 9 representative HCCs.
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and increased expression of vimentin, was detected in 8 of 9 (88.9%) 
HCC specimens with CHD1L overexpression. Conversely, increased 
expression of Cdc42-GTP was detected in 1 of 7 (14.3%) HCCs 
without CHD1L overexpression (Figure 8F). These results strong-
ly support that the molecular pathway of CHD1L-ARHGEF9- 
Cdc42-EMT may play a critical role in HCC progression.
Overexpression of CHD1L is associated with HCC metastasis and poor 
prognosis. To investigate the correlation between CHD1L overexpres-
sion and HCC metastasis, the expression level of CHD1L was com-
pared between primary HCCs and their paired metastatic tumors by 
IHC, using a tissue microarray (TMA) containing 50 pairs of primary 
and metastatic HCCs. Compared with their primary HCC tumors, 
increased expression of CHD1L was detected in 34 of 50 (68%) meta-
static HCC tumors (P < 0.001, Wilcoxon signed rank test; Figure 9A 
and Supplemental Table 4). These data further support the hypoth-
esis that CHD1L plays an important role in HCC metastasis.
To further confirm that CHD1L overexpression correlates with 
HCC prognosis, expression of CHD1L was examined by IHC in 
sections from 53 paraffin-blocked HCC specimens, with clinico-
pathological features including (but not limited to) tumor stage, 
venous metastasis, formation of microsatellite tumors, and dis-
ease-free survival (DFS) time. The results indicated that the overex-
pression of CHD1L was significantly associated with the presence 
of venous metastasis and the formation of microsatellite tumors 
(P < 0.05, Pearson χ2 test), which is considered evidence of intrahe-
patic tumor metastasis (ref. 29 and Table 1). Kaplan-Meier analysis 
revealed that overexpression of CHD1L was significantly associated 
with shorter DFS rate (log-rank, 4.776; P = 0.029; Figure 9B). The 
median DFS times in the CHD1L-negative HCC patient subgroup 
was 11.8 months (95% confidence interval, 4.4–19.2 months; n = 24), 
and the median time in the CHD1L-positive subgroup was 6.0 
months (95% confidence interval, 3.1–8.9 months; n = 29). Interest-
ingly, increased expression of CHD1L was often observed in tumor 
cells at the edge of the tumor and in cells invading to surrounding 
tissue and blood vessels (Figure 9, C–E). IHC staining of CD31, a 
well-known vascular endothelial marker, was used to confirm the 
invasion of tumor cells into the blood vessel (Figure 9E, right).
Discussion
The diverse nature of the targets identified in the present study 
reinforces the hypothesis that CHD1L binds to and regulates 
diverse classes of genes that affect a wide variety of cellular pro-
cesses. Genes associated with apoptosis, cell cycle, and signal 
transduction were relatively enriched in the CHD1L-bound loci, 
which is consistent with the known function of CHD1L (15, 16). 
In this study, we were particularly interested in the role of CHD1L 
in tumor cell migration, invasion, and metastasis through the 
upregulation of ARHGEF9 and the subsequent activation of Rho 
small GTPases. Rho GTPases function as molecular switches, 
cycling between inactive and active GDP-bound states. Like all 
members of the Ras superfamily, the activity of the Rho GTPases is 
determined by the ratio of their GTP/GDP-bound forms in the cell 
(30). The ratio of the 2 forms is regulated by the opposing effects 
of GEFs and GTPase-activating proteins. To date, accumulating 
evidence has demonstrated that the majority of mammalian GEFs 
specific for the Rho GTPases can promote cancer cell invasion by 
enhancing the loading of GTP onto Rho proteins (31–34).
In the present study, we found that CHD1L upregulated the 
expression of ARHGEF9, a GEF for Cdc42, which in turn acti-
vated Cdc42 in HCC cells. Although overexpression of Cdc42 has 
Figure 9
Overexpression of CHD1L is associated with HCC metastases and decreased DFS time. (A) Example of CHD1L expression detected in a 
primary HCC tumor and its metastatic tumor, with markedly stronger CHD1L staining in the latter. (B) Kaplan-Meier DFS survival curve of HCC 
patients in correlation with CHD1L expression. The DFS rate significantly decreased in the subgroup of HCC patients with CHD1L overexpres-
sion (red line; n = 29) compared with the CHD1L-negative subgroup (blue line; n = 24). (C–E) IHC staining with anti-CHD1L antibody showed that 
higher CHD1L expression was often observed in tumor cells at the tumor edge (C), invading (arrows) to surrounding tissue (D, left and right) and 
blood vessels (E, left). The endothelial cells of blood vessels were stained by IHC with an anti-CD31 antibody on the serial section of a clinical 
sample (E, right). Original magnification, ×200 (A and C–E).
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been detected in breast cancer (35) and in head and neck squa-
mous cell carcinomas (36), the role of Cdc42 in human carcino-
genesis remains unclear. Increased expression of Cdc42 has been 
also associated with HCC. One study found that the expression 
of Cdc42 was higher in HBV-associated HCC tumor tissue than 
in adjacent nontumor liver tissues (37). Another study found 
that Cdc42 was overexpressed in HCV-associated HCC in com-
parison to normal liver (38). In this study, we revealed that the 
upregulation of ARHGEF9 was significantly correlated with 
CHD1L overexpression in clinical HCC specimens and therefore 
able to increase the activation of Cdc42. All these findings suggest 
that ARHGEF9 is a CHD1L target gene and that the molecular 
circuitry established by CHD1L and ARHGEF9 promotes Cdc42 
activation during HCC progression.
During tumor progression, invasion, and metastasis, changes 
in the activity of Rho GTPase and the concomitant reorganiza-
tion of the actin cytoskeleton lead to loss of the interaction of 
adherens junctions and the cytoskeleton (21, 23, 27, 39). Among 
the 20 genes encoding different members of the Rho family, Rho 
(RhoA, RhoB, and RhoC), Rac (Rac1, Rac2, and Rac3), and Cdc42 
are 3 representative members that have been well defined for 
their role in modulating of the actin cytoskeleton (40). In 
fibroblasts and other cell types, RhoA activation induces 
formation of stress fibers, Rac1 stimulates lamellipodium 
formation, and Cdc42 induces filopodia (41). Rearrange-
ment of the actin cytoskeleton promotes cancer progres-
sion by promoting the acquisition of migratory and inva-
sive properties by dissociated cells, thereby allowing them 
to actively pass through the basement membrane and tra-
verse to distant organs. Therefore, we hypothesized that 
overexpression of CHD1L may play an important role in 
HCC invasion and metastasis. To confirm our hypothesis, 
both in vitro and in vivo assays — including wound heal-
ing assays, Matrigel invasion assays, and experimental 
metastasis assays — were used to study whether CHD1L 
overexpression promotes cell motility, tumor invasion, 
and metastasis. Our results demonstrated that CHD1L 
played a key role in HCC metastasis, and further stud-
ies indicated that the overexpression of CHD1L led to 
increased filopodia formation and cell motility as well as 
EMT. Moreover, these invasion- and metastasis-associ-
ated phenotypes could be effectively abolished by silenc-
ing ARHGEF9 expression in HCC cells that overexpressed 
CHD1L. These findings strongly suggest that the meta-
static function of CHD1L occurs through the ARHGEF9-
meidated activation of Cdc42.
It has been reported that Cdc42 contributes to cancer cell 
invasion via the EMT (42). The EMT is a key event in tumor 
invasion and metastasis in which epithelial cells lose epi-
thelial adherens and tight junction proteins, lose polarity 
and cell-cell contacts, and undergo remarkable remodeling 
of the cytoskeleton to facilitate cell motility and invasion 
(43, 44). The EMT includes loss of cell-cell adhesion and 
activation of mesenchymal markers as well as increased 
motility of tumor cells, which suggests that EMT is a 
major mechanism of tumor invasion and metastasis. To 
better elucidate the invasive and metastatic mechanisms 
of CHD1L, the effect of CHD1L overexpression or deple-
tion on the EMT was investigated. As expected, the epi-
thelial markers E-cadherin, α-catenin, and β-catenin were 
downregulated, whereas the mesenchymal markers N-cadherin, 
vimentin, and α-SMA were increased in CHD1L-tranfected cells. 
Similar results were also observed in tumors formed in nude mice 
induced by CHD1L-expressing cells. Further, silencing CHD1L 
expression in HCC cells inhibited EMT phenotype, invasive ability, 
and tumorigenesis in nude mice. Importantly, the EMT phenotype 
was also associated with overexpression of CHD1L in clinical HCC 
specimens. In addition, tumor invasion and tumor microsatellite 
formation were frequently detected in tumors induced by CHD1L-
expressing cells. All of these results clearly demonstrated that the 
EMT induced by CHD1L is an important mechanism underlying 
HCC development and metastasis.
Although curative surgery offers an opportunity for a cure in 
HCC patients, the postoperative tumor recurrence rate is high 
because of a high potential for vascular invasion and metastasis, 
with a cumulative 5-year recurrence rate ranging from 40% to 80% 
(2, 45). In the present study, the invasive and metastatic effect of 
CHD1L in clinical specimens was also addressed by IHC in 53 HCC 
specimens and an HCC TMA containing 50 pairs of primary and 
metastatic tumors. We found that the overexpression of CHD1L 
was significantly correlated with the presence of tumor microsatel-
Table 1
Clinicopathological correlation of CHD1L expression in HCC
Feature	 CHD1L	protein	expression
	 All	 Negative	 Positive	 P
Sex
Male 44 19 25
Female 9 5 4 0.715
Age
≤60 years 42 22 20
>60 years 11 2 9 0.086
Hepatitis	B	surface	Ag
Negative 5 1 4
Positive 48 23 25 0.362
Serum	AFP
log10 (ng/ml) 2.18 ± 1.50 2.33 ± 1.60 2.06 ± 1.45 0.543
Tumor	sizeA,B
≤5 cm 9 5 4
>5 cm 42 18 24 0.714
CirrhosisA
Absent 16 8 8
Present 35 16 19 1.000
Tumor	encapsulationA
Absent 33 15 18
Present 17 7 10 0.506
Microsatellite	formationA
Absent 31 18 13
Present 20 5 15 0.025
Venous	invasionA,C
Absent 26 16 10
Present 24 7 17 0.027
Tumor	stageA,D
Stage I 11 8 3
Stage II 27 11 16
Stage III 14 5 9 0.080
Values denote n except for serum AFP (mean ± SD). Significant differences 
are shown in bold. APartial data not available; statistic based on available data. 
BMeasured by the length of the largest tumor nodule. CDefined by findings on 
final pathological analysis (microscopic and major). DAmerican Joint Committee 
on Cancer classification.
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lite formation and venous metastasis in HCCs. More interestingly, 
the higher expression level of CHD1L was often detected in tumor 
cells invading into the surrounding tissue and blood vessel, which 
suggests that CHD1L plays an important role in tumor invasion. 
In addition, increased expression of CHD1L was detected in 66% 
of the metastatic HCC tumors compared with their paired prima-
ry HCCs. Furthermore, we also found that detection of CHD1L 
expression in tumor tissues could successfully distinguish a set 
of patients with increased risk of tumor recurrence or poor DFS 
rate. These findings directly demonstrate the clinical significance 
of CHD1L overexpression in HCC invasion and metastasis. We 
describe, for the first time to our knowledge, the invasive and met-
astatic mechanism involved in HCC progression: the transcrip-
tional regulator CHD1L upregulates ARHGEF9 transcription, 
which subsequently increases Cdc42 activity, causing filopodia 
formation, EMT, and finally HCC invasion and metastasis.
Methods
Patients and clinical specimens. Patients who underwent hepatectomy for HCC 
at the Cancer Center of Sun Yat-sen University were included in the ARH-
GEF9 and CHD1L correlation analysis (n = 35) and the clinicopathological 
correlation analysis (n = 53). None of these patients received preoperative 
chemotherapy or radiotherapy. All tumor samples were derived from dis-
sected tumor tissues and were composed of more than 90% of tumor cells 
without necrosis. The surgical specimens (both tumor and adjacent nontu-
mor tissue) were processed immediately after the operation and snap-frozen 
in liquid nitrogen (for protein, DNA, and RNA extraction) and/or embed-
ded in paraffin block (for pathological study). All HCC patients gave writ-
ten informed consent on the use of clinical specimens for medical research. 
Studies using human tissue were reviewed and approved by the Committees 
for Ethical Review of Research involving Human Subjects of Zhongshan 
University (Guangzhou, China) and University of Hong Kong.
Cell lines and culture conditions. The HCC cell lines QGY-7703 and PLC8024 
and an immortalized normal human liver cell line, LO-2, were obtained from 
the Institute of Virology, Chinese Academy of Medical Sciences (Beijing). 
The cells were maintained in high-glucose DMEM (Invitrogen) supple-
mented with 10% fetal calf serum (Invitrogen). The cells were incubated at 
37°C in a humidified chamber containing 5% CO2.
Plasmid constructs and transfection. The full-length CHD1L cDNA was 
amplified and cloned into the pCDNA3.1+ expression vector (Invitrogen) 
as described previously (15). pEGFP-CHD1L was generated by insert-
ing the cloned full-length CHD1L into pEGFP-N1 vector (Invitrogen) 
as described previously (16). The expression plasmids were transfected 
into cells using Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instructions.
Establishment of CHD1L knockdown cells. Based on the CHD1L sequence (NM_
004284), 2 shRNAs were designed using siRNA Target Finder (Ambion): 
shCHD1L-1, 5′-GCCAAGAGAAGGAGA-3′; shCHD1L-2, 5′-CGTATTGGA-
CATGCCACGAAA-3′. The oligoduplexes were cloned into the pRetroSuper 
(pRS) vector (Origene) or control pRS vector and transfected into PLC8024 
cells using Lipofectamine 2000 (Invitrogen). At 24 hours after transfection, 
transfected cells were selected for 2 weeks with 1 μg/ml puromycin (Origene). 
Pooled populations of knockdown cells, obtained 2 weeks after drug selection 
without subcloning, were subjected in both in vivo and in vitro experiments. 
Negative control cell lines were generated by infecting cells with pRS-shGFP 
construct targeting GFP cDNA (Origene), a purified and sequence-verified 
plasmid containing a noneffective 29-mer shGFP cassette.
Antibodies. Mouse anti-CHD1L antibody was purchased from Abcam. Rab-
bit anti–N-cadherin, –β-catenin, and –α-catenin antibodies were purchased 
as part of the Cadherin-Catenin Antibody Sampler Kit (Cell Signalling 
Technology). Mouse anti-vimentin, –E-cadherin, –α-SMA, –β-actin, and -
GAPDH antibodies were purchased from Santa Cruz Biotechnology. Mouse 
anti–E-cadherin antibody (ready to use for IHC) was purchased from Gen-
way Biotech Inc. Rabbit anti-CD31 antibody was purchased from Boster.
ChIP cloning. ChIP experiments were performed using an EZ-Magna 
ChIP G kit (Upstate Biotechnology) according to the manufacturer’s 
instructions. To facilitate cloning of the immunoprecipitated DNA frag-
ments, the purified DNA fragments were linked with an adaptor using 
primer A [GTTTCCCAGTCACGGTC(N)9] and random priming. The 
immunoprecipitated DNA fragments with adaptors were then ampli-
fied using the adaptor primer B [GTTTCCCAGTCACGGTC] and PCR. 
The enriched DNA fragments (about 200–400 bp) were purified with 
a PCR Purification Kit (Qiagen), cloned into the pGEM-T easy vector 
(Promega), and sequenced.
EMSA. Nuclear extracts (NEs) were prepared using the NucBuster Protein 
Extraction kit (Novagen). The probes were end-labeled with DIG by PCR 
using DIG-labeled dUTP (Roche) in addition to dNTPs. The probes were 
then purified by a PCR Purification Kit (Qiagen). EMSAs were performed 
with 10 μg NEs and 50 ng DIG-labeled or unlabeled probes in 1× binding 
buffer provided with the Bandshift Kit (Amersham Pharmacia Biotech). 
This binding reaction was separated on a nondenaturing polyacrylamide 
gel and transferred to a nylon membrane (Amersham Pharmacia Biotech). 
The resolved complexes were crosslinked using an UV crosslinker oven for 
3 minutes. The shifted bands corresponding to the protein-DNA com-
plexes were detected using a DIG Luminescent Detection Kit (Roche) and 
visualized using BioMax Light film (Kodak).
ChIP-PCR. The identified CHD1L binding sites were confirmed using 
independent ChIP-PCR assays with immunoprecipitated DNA fragments 
pulled down by anti-GFP antibodies FL and B-2, or pooled IgG from 
mouse and rabbit (Santa Cruz Biotechnology) as a negative control. The 
primers used for the amplification of the precipitated DNA fragments are 
listed in Supplemental Table 5.
qPCR. Total RNA was extracted using TRIzol Reagent (Invitrogen), 
and reverse transcription was performed using an Advantage RT-for-PCR 
Kit (Clontech Laboratories) according the manufacturer’s instructions. 
For qPCR analysis, aliquots of double-stranded cDNA were amplified 
using a SYBR Green PCR Kit (Applied Biosystems) and an ABI PRISM 
7900 Sequence Detector. The cycling parameters were 95°C for 30 sec-
onds, 55°C for 1 minute, and 72°C for 2 minutes for 45 cycles, followed 
by a melting curve analysis. Ct was measured during the exponential 
amplification phase, and the amplification plots were analyzed using 
SDS 1.9.1 software (Applied Biosystems). For the cell lines, the relative 
expression level (defined as fold change) of target gene is given by 2–ΔΔCt 
(ΔCt = ΔCttarget – ΔCt18S; ΔΔCt = ΔCt CHD1L-expressing or siCHD1L-8024 – ΔCtvector-
transfected or Con-8024) and normalized to the fold change detected in the cor-
responding control cells, which was defined as 1.0. For clinical HCCs 
and their matched nontumor specimens, the fold change of target gene 
is given by 2–ΔΔCt (ΔΔCt = ΔCttumor – ΔCtnontumor) and normalized to the 
average fold change in 35 nontumor tissues, which was defined as 1.0. 
All reactions were performed in duplicate. Primer sequences are listed in 
Supplemental Table 6.
RNAi. An siRNA (20 nM) against CHD1L, ARHGEF9, or GAPDH (Ambion) 
was transfected into cells in 6-well plates using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. Gene silencing was 
measured by qPCR and/or Western blot analysis 48 hours after transfection.
FISH. A BAC clone at 1q21 containing the CHD1L gene (RP11-337C18) 
was selected for interphase FISH study. BAC DNA and probe for chromo-
some 1 centromere were labeled with Spectrum-green (green signal) and 
Spectrum-red (red signal), respectively (Vysis). FISH reaction was per-
formed according to the method described previously (46).
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Western blot. Western blot analysis was performed as described previously 
(15). Signals were quantified by ImageJ software (http://rsb.info.nih.gov/ij) 
and defined as the ratio of target protein to β-actin. Data are presented as 
mean ± SD (n = 3).
Rho GTPase activation assay. This assay was performed using a Rac1/Cdc42 
Activation Kit (Upstate Biotechnology). The PAK1-P21-binding domain 
agarose beads provided in this kit were used to pull down Cdc42-GTP from 
whole cell lysates according to the manufacturer’s instructions. Cdc42-
GTP was then detected by Western blot using the Cdc42 monoclonal anti-
body provided in the kit.
F-actin and IF staining. After fixation with 4% paraformaldehyde in PBS for 
10 minutes, the cells were washed twice with PBS. For F-actin staining, cells 
were stained with Rhodamine phalloidin (Invitrogen). For IF staining, cells 
were incubated with the primary antibody (mouse anti–E-cadherin, -vimen-
tin, or –N-cadherin or rabbit anti–β-catenin; 1:100 dilution) overnight at 
4°C. After thorough washing, cells were then incubated with FITC-con-
jugated goat anti-mouse IgG (1:100 dilution, Santa Cruz Biotechnology) 
or Texas Red–conjugated goat anti-rabbit IgG (1:100 dilution, Santa Cruz 
Biotechnology). Finally, cells were washed and mounted with Mounting 
Medium containing DAPI (Vector Laboratories). Images were captured 
using a Leica DMRA fluorescence microscope (Rueil-Malmaison).
Wound healing and invasion assays. Cell migration was assessed by measur-
ing the movement of cells into a scraped, acellular area created by a 200-μl 
pipette tube, and the spread of wound closure was observed after 24 and 
36 hours and photographed under a microscope. Invasion assays were per-
formed with 24-well BioCoat Matrigel Invasion Chambers (BD) accord-
ing to the manufacturer’s instructions. The number of cells that invaded 
through the Matrigel was counted in 10 fields under a ×20 objective lens.
Tumor xenograft mouse model. Female athymic nude mice (4–5 weeks 
old) were housed under standard conditions and cared for according to 
the institutional guidelines for animal care. All animal experiments were 
approved by the Committee on the Use of Live Animals in Teaching and 
Research (CULATR), University of Hong Kong. For the xenograft tumor 
growth assay, control cells (Vec-LO2, Vec-7703, and Con-8024) were inject-
ed subcutaneously into the left dorsal flank of mice, and CHD1L-express-
ing or knockdown cells (CHD1L-LO2, CHD1L-7703, and shCHD1L-8024) 
were injected into the right dorsal flank of the same animal in a laminar 
flow cabinet. Tumor formation in nude mice was monitored over a 4-week 
period, and the tumor volume was measured weekly and calculated as 
0.5 × l × w2 (47). The mice were euthanized on the fifth or sixth week, and 
the tumors were excised and embedded in paraffin. Sections (5 μm) of 
tumors were stained with H&E to visualize the tumor structure.
Experimental metastasis assay. Male SCID-Beige mice (5 weeks old) were used, 
and each experimental group (Vec-7703 and CHD1L-7703) consisted of 6 
mice. Briefly, 2 × 105 cells were injected intravenously through the tail vein 
into each SCID mouse. All mice were euthanized 8 weeks after injection. The 
presence of tumor nodules was macroscopically determined, and the number 
of tumor nodules formed on the lung and liver surfaces was counted. The liv-
ers and lungs were excised and embedded in paraffin. All animal procedures 
were performed in full accordance with a CULATR-approved protocol.
TMA construction. A TMA block containing primary and matched meta-
static HCCs was constructed as described previously (48). TMA contained 
50 pairs of primary HCCs and their matched metastatic tumors from the 
same patients. These tumor samples were collected from archives of paraffin- 
embedded tissues obtained between 1997 and 2003 at the Department of 
Pathology, Sun Yat-sen University. Metastatic tumors included 28 intrahepat-
ic metastases (23 portal vein, 5 cholangiotube) and 22 extrahepatic metasta-
ses (16 peritoneum, 5 lymph nodes, 1 kidney). Multiple sections (5 μm thick) 
were cut from the TMA block and mounted on microscope slides.
IHC. The paraffin-embedded tissue blocks were sectioned for IHC. In brief, 
sections were deparaffinized and rehydrated. The endogenous peroxidase 
activity was blocked with 3% H2O2 for 10 minutes. For the antigen retrieval, 
slides were immersed in 10 mM citrate buffer (pH 6.0) and boiled for 15 
minutes in a microwave oven. Nonspecific binding was blocked by 5% nor-
mal goat serum for 10 minutes. The slides were incubated with a 1:50 dilu-
tion of monoclonal antibody against CHD1L (Abcam) at 4°C overnight in 
a moist chamber. The slides were sequentially incubated with biotinylated 
goat anti-mouse IgG (1:100 dilution; Santa Cruz Biotechnology) and then 
streptavidin-peroxidase conjugate, each for 30 minutes at room temperature. 
Isotope-matched human IgG was used in each case as a negative control. 
Finally, the 3, 5-diaminobenzidine (DAB) Substrate Kit (Dako) was used for 
color development followed by Mayer hematoxylin counterstaining.
Statistics. Unless otherwise indicated, data are presented as mean ± SD 
of 3 independent experiments. The SPSS statistical package for Windows 
(version 16; SPSS) was used for data analysis. Based on staining intensi-
ties, the CHD1L immunoreactivity was scored as negative (0 to 1) and 
positive (2 to 3) according to a previously reported semiquantitative scor-
ing method (49). The clinicopathological features in CHD1L-positive and 
-negative patients were compared using Pearson χ2 test for categorical 
variables and independent Student’s t test for continuous data. Kaplan-
Meier plots and log-rank tests were used for survival analysis. DFS times 
were calculated from data of curative surgery to HCC recurrence, death, 
or the last follow-up data. For TMA analysis, based on IHC scores, CHD1L 
protein levels in primary HCC tissues and their matched metastatic tis-
sues were compared using Wilcoxon signed rank test. The mRNA level 
of CHD1L and ARHGEF9 in the HCCs and the matched nontumor tis-
sue was compared using paired Student’s t test. The correlation between 
mRNA levels of CHD1L and ARHGEF9 was analyzed using Pearson χ2 
test. The independent Student’s t test was used to compare the invasive 
ability between any 2 preselected groups. A P value less than 0.05 was con-
sidered statistically significant.
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